Pro-inflammatory signaling by IL-10 and IL-22: bad habit stirred up by interferons? by Mühl, Heiko
HYPOTHESIS ANDTHEORY ARTICLE
published: 04 February 2013
doi: 10.3389/ﬁmmu.2013.00018
Pro-inﬂammatory signaling by IL-10 and IL-22: bad habit
stirred up by interferons?
Heiko Mühl*
Pharmazentrum Frankfurt/ZAFES, University Hospital Goethe-University Frankfurt, Frankfurt am Main, Germany
Edited by:
Masaaki Murakami, Osaka University,
Japan
Reviewed by:
Masato Kubo,Tokyo University of
Science, Japan
Daisuke Kamimura, Osaka University,
Japan
*Correspondence:
Heiko Mühl, Pharmazentrum
Frankfurt/ZAFES, General
Pharmacology andToxicology,
University Hospital Goethe-University
Frankfurt,Theodor-Stern-Kai 7 , 60590
Frankfurt am Main, Germany.
e-mail: h.muehl@em.uni-frankfurt.de
Interleukin (IL)-10 and IL-22 are key members of the IL-10 cytokine family that share char-
acteristic properties such as deﬁned structural features, usage of IL-10R2 as one receptor
chain,andactivationofsignaltransducerandactivatoroftranscription(STAT)-3asdominant
signalingmode.IL-10,formerlyknownascytokinesynthesisinhibitoryfactor,iskeytodeac-
tivation of monocytes/macrophages and dendritic cells. Accordingly, pre-clinical studies
document its anti-inﬂammatory capacity. However, the outcome of clinical trials assessing
the therapeutic potential of IL-10 in prototypic inﬂammatory disorders has been disappoint-
ing. In contrast to IL-10, IL-22 acts primarily on non-leukocytic cells, in particular epithelial
cells of intestine, skin, liver, and lung. STAT3-driven proliferation, anti-apoptosis, and anti-
microbial tissue protection is regarded a principal function of IL-22 at host/environment
interfaces. In this hypothesis article, hidden/underappreciated pro-inﬂammatory character-
istics of IL-10 and IL-22 are outlined and related to cellular priming by type I interferon. It
is tempting to speculate that an inherent inﬂammatory potential of IL-10 and IL-22 con-
ﬁnes their usage in tissue protective therapy and beyond that determines in some patients
efﬁcacy of type I interferon treatment.
Keywords: inﬂammation, type I interferons, interleukin-10, interleukin-22, signal transducer and activator of
transcription
INTRODUCTION
Type I interferon (IFN), interleukin (IL)-10, and IL-22 are
cytokines that accomplish fundamental tasks in tailoring
immunoactivation in a broad array of pathophysiological con-
ditions. Whereas clinical use of type I IFN is well-established
for immunomodulation in multiple sclerosis patients, therapy of
hepatitis B/C virus infections, and treatment of some speciﬁc
forms of malignancies, trials evaluating IL-10 in human disease
so far did not translate into clinical practice. Phase I clinical trials
assessing application of IL-22 to healthy volunteers have just been
initiated. Herein, I concisely introduce into the biology of type I
IFN, IL-10, and IL-22. Then, spotlight will be thrown on speciﬁc
pro-inﬂammatory properties of IL-10 and IL-22 that,particularly
in the case of IL-10, call attention at second glance, may relate to
interactionswithtypeIIFN,andpotentiallyconﬁneusageof both
cytokines in tissue protective therapy.
TYPE I IFN: MULTIFACETED MODULATOR OF INFLAMMATION
Efﬁcient production of type I IFN, consisting of IFNa subtypes
and IFNb as well as IFNk, IFN+, and IFN&, is pivotal for host
defense against viral infections (González-Navajas et al., 2012).
This decisive function can be observed in animal models (van den
Broek et al., 1995) as well as human disease (Zhang et al., 2008a)
andhasbeensuccessfullytranslatedintoclinicalpracticetargeting
hepatitis B/C virus infection (Chevaliez and Pawlotsky, 2007). In
addition,type I IFN displays a strong capacity for immunomodu-
lation with stunning context-speciﬁc diversity (Prinz and Kalinke,
2010; Trinchieri, 2010; Axtell et al., 2012; González-Navajas et al.,
2012).Infact,animalmodelsdemonstrateprotectionbytypeIIFN
in experimental arthritis (Treschow et al.,2005),colitis (Katakura
etal.,2005),andmultiplesclerosis(Teigeetal.,2003).Amongoth-
ers,anti-inﬂammatory properties of IFNa/b include inhibition of
Th1 (McRae et al., 1998; Axtell et al., 2010) and Th17 cell devel-
opment (Guo et al., 2008; Ramgolam et al., 2009; Axtell et al.,
2010) and reduction of IL-1b/IL-18 biological activity (Reznikov
et al., 1998; Kaser et al., 2002; Guarda et al., 2011; Wittmann
et al.,2012). Recently,the therapeutic potential of IFNb was thor-
oughly analyzed in a murine adoptive Th1/Th17 transfer model
of autoimmune encephalomyelitis (EAE). This study exemplar-
ily exposed the multifaceted mode of IFNb immunomodulation.
Speciﬁcally, IFNb administration was protective in Th1-induced
EAE but actually aggravated disease subsequent to transfer of
fully differentiated pathogenic Th17 cells (Axtell et al.,2010). This
complexity reﬂects the split therapeutic efﬁcacy of IFNb which is
approved for treatment of multiple sclerosis patients. Notably, at
least one third of patients do not respond to cytokine treatment
and data actually suggest that IFNb therapy may even worsen
disease in some patients (Axtell et al., 2012). Pro-inﬂammatory
characteristicsof typeIIFNarenotrestrictedtoestablishedTh17-
inducedEAE.Infact,IFNa/blikewisemediatepathogenesisintwo
models of experimental psoriasis, namely in the human/murine
xenograft (Nestle et al., 2005) and the interferon regulatory fac-
tor (IRF)-2 knockout model (Hida et al., 2000). Circumstantial
evidence obtained from patients with hepatitis C virus infection
or multiple sclerosis indeed points to the inherent capability of
type I IFN to mediate symptoms of psoriasis (Webster et al.,1996;
Downs and Dunnill, 2000; La Mantia and Capsoni, 2010). Patho-
genicfunctionsof IFNa/bmayincludethefollowingmechanisms:
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upregulationof dendriticcell(DC)differentiationandactivity(Le
Bon et al., 2001; Severa et al., 2007; Farkas and Kemény, 2011; Li
et al.,2011),activation of natural killer (NK) cells (Sareneva et al.,
2000; Matikainen et al., 2001; Swann et al., 2007; Zhu et al., 2008;
Hansen et al.,2011),activation of B cells (Krumbholz et al.,2008),
as well as activation of neutrophils with inhibition of neutrophil
apoptosis and enhanced release of immunostimulatory extracel-
lular traps (Wang et al., 2003; Martinelli et al., 2004; Mantovani
et al., 2011).
Binding of IFNa/b to their common receptor IFNAR (Novick
et al., 1994) initiates TYK2/JAK1-directed receptor phosphoryla-
tion with subsequent activation of signal transducer and activator
of transcription (STAT) proteins, foremost STAT1 and STAT2.
Those establish STAT1 homodimers or STAT1/STAT2/IRF9 het-
erotrimers that,by acting as transcription factors,mediate expres-
sion of genes controlled by g-activated sites (GAS) or IFN-
stimulated response elements (ISRE), respectively. Besides those
two major pathways, IFNa/b are capable of activating to some
degree further modes of signal transduction in a cell type speciﬁc
manner (Ivashkiv,2003;Platanias,2005;Takaoka andYanai,2006;
deWeerdetal.,2007).Altogether,signalingresultsingenerationof
a speciﬁc gene expression proﬁle coined“the IFN signature”(van
Baarsen et al., 2008).
Notably,cellularprimingbyIFNa/brobustlyaffectsthebiology
of diverse cytokines, speciﬁcally those that likewise act via STAT
proteins (Taniguchi and Takaoka, 2001; Ivashkiv, 2003; Gough
etal.,2012).Herein,potentialinteractionsbetweentypeIIFNand
IL-10/IL-22 are broadly discussed with focus on signaling in the
context of inﬂammation.
IL-10: AN ANTI-INFLAMMATORY CYTOKINE
Along with transforming growth factor (TGF)-b (Kulkarni et al.,
1995) and IL-37 (Nold et al., 2010), IL-10, formerly known
as cytokine synthesis inhibitory factor (Fiorentino et al., 1989)
and namesake of the corresponding cytokine family, is regarded
a key immunoregulatory cytokine capable of curbing overt
inﬂammation in various pathophysiological settings. Those anti-
inﬂammatory functions are consequences of IL-10 receptor (R)-
1/IL-10R2 heterodimeric receptor ligation, are predominantly
mediated by subsequent STAT3 activation, and associate par-
ticularly with deactivation of monocytes/macrophages and DC
(Ouyang et al., 2011; Hofmann et al., 2012; Kubo and Motomura,
2012; Paul et al., 2012). Speciﬁcally, production of prototypic
pro-inﬂammatory cytokines such as IL-1, tumor necrosis factor
(TNF)-a, and IL-12 is potently inhibited by IL-10 in the afore-
mentioned cell types (de Waal Malefyt et al., 1991; Fiorentino
etal.,1991;Isleretal.,1999;Corintietal.,2001).Molecularmech-
anisms underlying this modulatory action of IL-10 are still cloudy
butlikelytargetthepro-inﬂammatorytranscriptionfactornuclear
factor-kB (NF-kB; Bhattacharyya et al., 2004) and additionally
include modes of post-transcriptional regulation (Kontoyiannis
et al., 2001). Both of these principles of IL-10 action have been
demonstratedforactivatedmurineDCandtheirassociatedTNFa
production. DC are in fact supposed to be a key target of IL-10
action. Notably, by reducing DC-derived IL-12 or IL-23, IL-10 is
in particular capable of weakening Th1 or Th17 differentiation,
respectively (Ouyang et al., 2011; Paul et al., 2012). In addition to
inﬂuencing the cytokine network,IL-10 has the capability to curb
production of key effector mediators involved in development of
tissue damage, among others reactive oxygen species (Kuga et al.,
1996)andmatrixmetalloproteinases(Johnetal.,2002;Noldetal.,
2003).
Regulatory effects of IL-10 as detected on the cellular level
mirror its remarkable potency to ameliorate disease in rodent
models of inﬂammation, among others collagen-induced arthri-
tis (Walmsley et al., 1996), endotoxemia (Hofstetter et al., 2005),
and experimental colitis (Duchmann et al., 1996). Recently, the
crucial role of endogenously produced IL-10 for the pathogenesis
of human inﬂammation has been proven. In fact, patients with
IL-10 or IL-10 receptor defects develop an early-onset,severe,and
monogenicinﬂammatoryboweldisease(IBD)thatisexceptionally
hard-to-treat (Glocker et al., 2011).
Despite encouraging pre-clinical data suggesting this cytokine
as therapeutically valuable biological,results of clinical trials eval-
uating the merit of IL-10 administration in chronic inﬂammation
havebeenpreponderantlydisappointing.Althoughagoodcasefor
potential IL-10 therapy, the outcome of placebo-controlled clini-
cal trails for treatment of psoriasis vulgaris was not as clear-cut as
expectedanddemandsanalysisof largerpatientgroups(Friedrich
etal.,2002;Kimballetal.,2002).ApplicationofIL-10fortreatment
of active rheumatoid arthritis (RA) likewise produced inconclu-
sive results with, at best, a marginal trend toward amelioration of
disease (Brennan, 1999). Finally, trials assessing efﬁcacy of IL-10
administration in IBD patients,either suffering from Crohn’s dis-
ease or ulcerative colitis, once more, uncovered lack of signiﬁcant
clinical beneﬁt associated with this therapeutic strategy (Danese
et al., 2008; Buruiana et al., 2010).
IL-22: A TISSUE PROTECTIVE CYTOKINE
IdentiﬁedasIL-10-relatedTcell-derivedinduciblefactor(IL-TIF)
or IL-22 (Dumoutier et al., 2000; Xie et al., 2000) this IL-10 fam-
ily member shares decisive structural and biochemical properties
with its cytokine companion IL-10. Although human IL-10 and
IL-22displaylimited25%aminoacididentity,bothexhibitcharac-
teristic bundle-forming clustering of a-helices which structurally
deﬁnes members of the IL-10 cytokine family (Ouyang et al.,
2011).Celltypesprincipallycapableof producingIL-10andIL-22
partially overlap which applies to activated Th1 and CD8C T cells
(Bachmannetal.,2010;Wolketal.,2010;Ouyangetal.,2011),NK
cells (Mehrotra et al.,1998; Colonna,2009;Wolk et al.,2010),and
DC (Pickert et al., 2009; Ouyang et al., 2011). Beyond that, Th17
(Miossecetal.,2009),Th22(Duhenetal.,2009),andlymphoidtis-
sueinducer-likecells(Colonna,2009)cangenerateampleamounts
of IL-22. To activate target cells, IL-22 employs a heterodimeric
receptor complex consisting of IL-22R1 and, most notably, IL-
10R2. In further analogy to IL-10, signal transduction engaged
by IL-22 is seemingly dominated by STAT3 activation (Aujla and
Kolls, 2009; Wolk et al., 2010) with subsequent induction of pro-
totypic STAT3 downstream genes, among others suppressor of
cytokine signaling (SOCS)-3 (Ito et al., 1999; Nagalakshmi et al.,
2004;Hoegl et al.,2011). Despite far going similarities,differences
between IL-10 and IL-22 are noteworthy and particularly apply to
their respective target cell populations. Speciﬁcally, as a result of
tightly regulated IL-22R1 expression, functional IL-22 receptors
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are predominantly found on cells of epithelial origin including
intestinal and lung epithelial cells,keratinocytes,and hepatocytes.
In stark contrast to IL-10, leukocytes thus generally lack IL-22
responsiveness (Wolk et al.,2004). Restriction of IL-22R1 to non-
leukocytic cells actually determines IL-22 function in biological
systems. This notion has been impressively demonstrated using
transgenic mice that artiﬁcially express IL-22R1 on lymphocytes.
Those mice develop normally,however display lethal multi-organ
inﬂammation 2–3months after birth (Savan et al., 2011).
Properties of IL-22 in (patho-)physiology reﬂect on the one
hand selective non-leukocytic expression of functional recep-
tors in the liver and at host/environment interfaces and on the
other hand fundamental tasks of STAT3 in health and disease
(Jarnicki et al., 2010; Wang et al., 2011). Pivotal STAT3 func-
tions include activation of anti-apoptosis and proliferation. Both
cellular responses speciﬁcally connect to biological functions of
IL-22 in lung (Aujla et al., 2008; Zhang et al., 2008b) and intesti-
nal epithelial cells (Brand et al., 2006; Pickert et al., 2009) as
well as in hepatocytes (Pan et al., 2004; Radaeva et al., 2004)
and liver stem/progenitor cells (Feng et al., 2012). Accordingly,
rodent models demonstrate tissue protection by IL-22 in the
context of intestinal wounding (Pickert et al., 2009), ventilator-
induced lung injury (Hoegl et al., 2011), and hepatic insults sub-
sequent to ischemia-reperfusion injury (Chestovich et al., 2012)
or intoxication by concanavalin A, carbon tetrachloride (Pan
et al., 2004; Radaeva et al., 2004; Zenewicz et al., 2007), alco-
hol (Xing et al., 2011) as well as acetaminophen (Scheiermann
et al., 2012). Moreover, IL-22 exhibits a protective potential in
infection/microbe-driven intestinal (Zenewicz et al., 2008; Sugi-
moto et al., 2008; Zheng et al., 2008) or pulmonary inﬂamma-
tion (Aujla et al., 2008). Besides aforementioned tissue protective
modes, this speciﬁc function of IL-22 is based on strengthen-
ing of the anti-bacterial arsenal at host/environment interfaces
by mechanisms that likely include upregulation of anti-bacterial
peptides such as b-defensins, lipocalin, or RegIIIb/g, ampliﬁca-
tion of anti-bacterial inducible nitric oxide synthase (iNOS), and
enhanced epithelial mucus production (Ziesché et al., 2007; Aujla
and Kolls, 2009; Blaschitz and Raffatellu, 2010; Mühl et al., 2011;
Sonnenberg et al., 2011; Eddens and Kolls, 2012). Induction of
SOCS proteins (Nagalakshmi et al., 2004; Hoegl et al., 2011) and
of anti-inﬂammatory IL-10 (Nagalakshmi et al., 2004) by IL-22
may additionally be crucial for ﬁne-tuning local inﬂammation at
epithelial sites of tissue damage. Altogether, IL-22 appears piv-
otal for stabilization of epithelial integrity and homeostasis upon
injurious, noxious, and infectious challenge. Since IL-22 applica-
tion to healthy mice appears neither be connected to induction of
acute inﬂammation nor to overt immunosuppression as assessed
by analysis of basal and endotoxin-induced systemic levels of
inﬂammatory cytokines (Wolk et al., 2004; Scheiermann et al.,
2012), current data on the whole suggest short-term usage of this
cytokine for tissue protective therapy. Recently, a phase I clinical
trialcharacterizingthesafetyproﬁleofIL-22applicationtohealthy
volunteers has been initiated.
PRO-INFLAMMATORY PROPERTIES OF IL-10 AND IL-22
Bulk of pre-clinical data and analysis of patients with IL-10
or IL-10 receptor defects (Glocker et al., 2011) clearly point
to endogenously produced IL-10 as potent and signiﬁcant
anti-inﬂammatory determinant. However, thorough analysis fur-
ther suggests that IL-10 has the potential to acquire janus-faced
properties in an inﬂammatory environment in vivo. In recent
years several studies have been performed in order to verify
the human response upon IL-10 administration, particularly in
view of its anti-inﬂammatory potential. Those clinically impor-
tant studies disclosed perplexing pro-inﬂammatory functions of
IL-10.
EspeciallyrevealinghasbeenastudyinvestigatingIL-10admin-
istration in human experimental endotoxemia(Lauw et al.,2000).
Inthiswell-controlledsetting,IL-10,given1hsubsequenttoendo-
toxin, actually potentiated systemic levels of inﬂammatory IFNg
and its downstream chemokine target genes CXCL10 (IP10) and
CXCL9(MIG).Surprisingly,serumlevelsof TNFawerenotinhib-
ited by IL-10 given 1h after endotoxin. Stimulatory effects of
IL-10 connected to upregulation of CD8C T and NK cell activ-
ity as detected by increased serum granzyme concentrations. Data
essentially agree with a study assessing IL-10 treatment of Crohn’s
disease patients (Tilg et al., 2002). Here, administration of IL-10
mediatedariseinserumneopterin,awell-characterizedsurrogate
marker of IFNg bioactivity and macrophage activation (Huber
et al., 1984). In addition, IFNg production as detected in ex vivo
whole blood assays was augmented in cultures derived from IL-
10-treated patients (Tilg et al.,2002). A further study on psoriasis
patients undergoing IL-10 therapy conﬁrmed induction of sys-
temic neopterin by IL-10 and demonstrated enhanced ex vivo NK
cell-derived IFNg production by cells obtained from cytokine-
treatedpatients. Inaddition,patients of theIL-10 groupdisplayed
signiﬁcantly increased serum levels of C-reactive protein, a stan-
dard marker indicating clinical immunoactivation, and of the
solubleIL-2receptor(Döckeetal.,2009)whichisregardedasurro-
gate marker of T cell activation (Witkowska, 2005). Finally, IL-10
administration was evaluated for treatment of systemic inﬂam-
mation due to a Jarisch–Herxheimer reaction in patients infected
with Borrelia recurrentis. IL-10 did not affect clinical course of
systemic inﬂammation. Surprisingly, there was an unexpected
trend toward increased production of IL-6, IL-8, and TNFa upon
IL-10 treatment that, however, did not reach the level of statis-
tical signiﬁcance in the group of patients investigated (Cooper
et al.,2000). Altogether,human in vivo studies indicate a complex
action of IL-10 when administered in an inﬂammatory context.
Those clinical observations certainly do not echo clear-cut data
obtained in deﬁned rodent models of diseases which propose IL-
10 as potent and reliable anti-inﬂammatory cytokine. In essence,
IL-10 application to humans displays an immunostimulatory
component which results in induction of speciﬁc inﬂammatory
parameters, among others IFNg, neopterin, and C-reactive pro-
tein. This aspect of IL-10 biological activity appears to connect
especially to activation of distinct macrophage-, NK-, and T cell
subsets.
The basis of IL-10 immunostimulatory action remains cloudy.
However,afewreportsfocusingonNKandTcellsshedsomelight
on this piece of IL-10 biology. Although IL-10 is often considered
an important negative signal for NK cell activation, data on that
issuearenotunequivocal(Souza-Fonseca-Guimaraesetal.,2012).
Infact,earlyworkdemonstratesthatIL-10iscapableof enhancing
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murine NK cell-derived IFNg in the context of IL-12/IL-18 (Shi-
bata et al.,1998) or IL-18 (Cai et al.,1999) stimulation. The latter
study also shows increased NK cell proliferation and cytotoxicity
undertheinﬂuenceof IL-10(Caietal.,1999).IL-10alsoincreased
NK cell cytotoxicity and IFNg production in murine DC/NK cell
cocultures(Qianetal.,2006).SinceIL-10likewisehasthecapabil-
itytoupregulatecytolyticactivityof humanNKcells(Paratoetal.,
2002; Park et al.,2001) this stimulatory IL-10 action apparently is
not a species speciﬁc phenomenon.
Activated T cells, either of CD4C or CD8C nature, are a sig-
niﬁcant source of inﬂammatory cytokines, among others IFNg.
Besides the antigen-dependent mode of T cells activation, par-
ticularly memory helper CD4C and cytotoxic CD8C T cells but
also naïve CD4C T cells can produce ample amounts of IFNg in
an antigen-independent but cytokine-driven manner (Berg et al.,
2003; Munk et al., 2011). T cells can thus be regarded as mul-
tifaceted components of adaptive and even innate immunity that
undergomultilayeredactivationmodesforinductionofcytokines.
Recent data on CD8C T cell activation by IL-10 add a further
layer of complexity. Authors demonstrate in murine experimen-
tal breast cancer that subcutaneous injection of pegylated IL-10
results in potentiation of CD8C T cell-dependent intratumoral
IFNgexpressionwhichassociateswithgrowthinhibitionandpar-
tial rejection of established tumors. Interestingly, splenic IFNg
expression distant from the tumor site was likewise increased
upon IL-10 treatment. In an in vitro assay, IL-10 also increased
IFNg production by human CD8C T cell in the context of poly-
clonal stimulation by anti-CD3/anti-CD28 (Mumm et al., 2011).
Notably, IL-10-induced activation of CD8C cytotoxic T cells with
accompaniedIFNgproductionconcurswithpreviousdata(Santin
et al., 2000).
A well-established property of IL-10 is its capability to pro-
mote proliferation,differentiation,and antibody production by B
cells. Accordingly, IL-10 is supposed to be pathogenic in diseases
driven by overt antibody production and subsequent detrimen-
talimmune-complexdeposition.Oneprominentexampleof such
diseases is systemic lupus erythematosus (SLE; Beebe et al.,2002).
In fact, IL-10 neutralization displays therapeutic efﬁcacy in SLE
patients (Llorente et al., 2000).
Interleukin-22 has been related to the pathogenesis of some
prototypic autoimmune diseases. Speciﬁcally, IL-22 apparently
serves pathogenic functions in RA where its serum levels correlate
with disease activity in patients (Leipe et al., 2011). Accordingly,
IL-22 deﬁciency ameliorates murine collagen-induced arthritis
(Geboes et al., 2009). Main cellular targets of IL-22 in RA are
synovial ﬁbroblasts. In this cell type, IL-22 induces prolifera-
tion, expression of the pro-inﬂammatory chemokine monocyte
chemoattractant-1 (MCP-1; Ikeuchi et al., 2005), and of recep-
tor activator of NF-kB ligand (RANKL). The latter target directly
connects IL-22 to joint destruction (Kim et al., 2012). A further
example of pathogenic IL-22 functions is psoriasis. In fact, IL-
22 is vastly expressed in psoriatic lesional skin (Boniface et al.,
2007) and its serum levels correlate with disease activity (Naka-
jimaetal.,2011).Notably,IL-22deﬁciencyorblockageameliorates
diseaseinexperimentalpsoriasis(VanBelleetal.,2012).Moreover,
transgenic mice expressing IL-22 develop psoriasis-like symp-
toms (Wolk et al., 2009; Park et al., 2011). Key pathophysiological
functions of dermal IL-22 comprise of modulating keratinocyte
differentiationandupregulationofinﬂammatoryparameterssuch
as CXCL5 (ENA-78), IL-20, and matrix metalloproteinases-1 and
-3 (Boniface et al., 2005; Nograles et al., 2008; Sabat and Wolk,
2011). Altogether, present data suggest IL-22 as promising target
for immunomodulation in psoriasis patients.
Experimental observations indicate that IL-22 application in
murine endotoxemia fails to signiﬁcantly affect production of the
pro-inﬂammatory cytokines TNFa, IL-6, and IFNg analyzed in
the early phase (up to 8h after onset of endotoxemia) of the syn-
drome (Wolk et al., 2004; Scheiermann et al., 2012). However,
in more prolonged endotoxemia IL-22 knockout mice displayed
reduced mortality, an observation that became apparent 16h
post endotoxin application. This latter study suggests that IL-
22 may serve pathogenic functions during temporally extended
endotoxin-drivensystemicinﬂammation(Dumoutieretal.,2011).
Current knowledge on the role of IL-22 in the pathogene-
sis of viral infections is merely fragmentary. Although generally
being hepatoprotective,IL-22 actually aggravates disease in exper-
imental hepatitis B virus infection which appears to be mediated
by IL-22-driven expression of chemokines such as CXCL9 and
CXCL10 (Zhang et al., 2011). IL-22 likewise serves pathogenic
functions in murine West Nile virus encephalitis by enhancing
cerebral chemokine expression, speciﬁcally that of CXCL1 (KC)
and CXCL5 (Wang et al., 2012). In contrast, IL-22 appears to
be protective in inﬂuenza virus A infection (Kumar et al., 2013;
Paget et al., 2012) which likely relates to the profound capacity
of this cytokine to preserve epithelial integrity at the pulmonary
host/environment interface (Aujla et al., 2008; Hoegl et al., 2011).
IFN PRIMING EXPOSES A LAYER OF PRO-INFLAMMATORY
SIGNALING ACTIVATED BY IL-10 AND IL-22
Priming of cells by type I IFN is able to modify subsequent
responsestoothercytokines.Interestingly,thisrelatesinparticular
to those cytokines that likewise signal via STAT proteins (Gough
et al.,2012). This well-known capability of IFNa/b should signiﬁ-
cantly impact on cytokine biology since production of type I IFN
is not merely upregulated by infections but also by inﬂammation
in the context of autoimmunity and beyond that by more general
means of cellular stress (Taniguchi and Takaoka, 2001; Kalliolias
andIvashkiv,2010).Thislatterphenomenonofinductionbystress
is exempliﬁed by IFNa/b mRNA upregulation upon serum with-
drawalincultivatedﬁbroblasts(TaniguchiandTakaoka,2001)and
may form the basis of frequently recognized basal expression of
type I IFN.
In fact, regulation of cytokine signaling by IFNa/b also applies
to cellular activation by IL-10 or IL-22. Previous data by Ivashkiv
andcolleaguesonmacrophageprimingbyIFNandeffectsonsub-
sequent IL-10 signaling are pivotal in this context. Interestingly,
IFNaprimingpotentiatesthecapabilityof IL-10toactivateSTAT1
and succeeding induction of pro-inﬂammatory CXCL9/CXCL10
in human macrophages (Sharif et al.,2004). This priming process
is presumably mediated by STAT1 because IFNg likewise con-
vertsIL-10intoaSTAT1activatingcytokine(Herreroetal.,2003).
Notably,a decisive difference between type I IFN and IFNg is that
production of the latter is regulated much more stringently. In
fact, almost all cells of the body are capable of producing type
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I IFN (González-Navajas et al., 2012) which may, upon suitable
stimulatory conditions in vivo, rapidly provide local IFN levels
sufﬁcient for immunoregulation. Observations altogether suggest
that STAT1 signaling primes for subsequent STAT1 activation,
a process reminiscent of classical preconditioning phenomena.
Such priming mechanism, may also apply to human pathophys-
iology. In fact, genome-wide analysis of ex vivo stimulated syn-
ovial ﬂuid macrophages derived from RA patients revealed the
notable capability of IL-10 to induce a gene expression proﬁle
akin to that of IFNg (Antoniv and Ivashkiv, 2006). Notably, IFNb
is upregulated in the RA synovium (van Holten et al., 2005).
A similar regulatory loop affecting IL-10 biological properties
might also be in place in murine macrophages, though direct
proof of that is currently missing.Yet,IL-10 signiﬁcantly increases
iNOS-derived nitrite production by endotoxin- (lipopolysaccha-
ride, LPS)-stimulated murine J774 macrophages (Jacobs et al.,
1998). Under those conditions,rapid induction of IFNb,maximal
within 2h of LPS-stimulation, may contribute to ampliﬁcation
of nitrite release from macrophages co-stimulated with IL-10
(Fujihara et al., 1994).
Most recently, we investigated effects of IFNa priming on IL-
22 signal transduction and noted, in similarity to data on IL-10,
ampliﬁcation of IL-22-activated STAT1 in primed cells. Con-
version of IL-22 into a cytokine efﬁciently activating STAT1 by
pretreatment with IFNa became apparent in diverse human cell
types such as DLD1 and Caco2 colon carcinoma cells, HepG2
hepatomacells,andprimarykeratinocytes.STAT1activationasso-
ciated with induction of prototypic pro-inﬂammatory STAT1
target genes such as CXCL9 and CXCL10. By using the viral
mimic polyinosinic:polycytidylic acid and the IFNa/b antago-
nist B18R we also demonstrate in that study the capability of
endogenously produced type I IFN to shape IL-22 signal trans-
duction (Bachmann et al., 2012). Especially qualitative effects of
IFNa/b priming on IL-10/IL-22 signaling should be pathophysio-
logically crucial. As already alluded to, STAT3 confers predom-
inantly pro-proliferative, anti-apoptotic, and pro-tumorigenic
signals. Provided by IL-10, temporal extended STAT3 activa-
tion moreover is key to restraining inﬂammatory functions of
macrophage/DC populations. In contrast, STAT1 connects to
apoptosis,suppressionofneoplasia,andenforcedTh1-likeinﬂam-
mation (Paludan, 2000; Yu et al., 2009; Ouyang et al., 2011;
Kubo and Motomura, 2012). Accordingly, the balance of cel-
lular STAT1/STAT3 activation is likely one of the crucial fac-
tors that determine the long-term outcome of inﬂammatory
conditions.
Molecular mechanisms underlying regulation of cytokine sig-
naling,includingthatofIL-10andIL-22,bytypeIIFNarenotfully
understoodbutlikelyincludeactiononthelevelofcytokinerecep-
torsandupregulationof STAT1proteinexpression.Awell-studied
prototypic target of IFNa/b priming represents IFNg receptor
(IFNGR) signaling which is actually impaired in cells display-
ing lack of IFNAR activation. Analysis of this effect brought to
light physical interactions between IFNAR and IFNGR receptor
components that, distal to STAT1 phosphorylation, facilitate gen-
eration of phospho-STAT1 homodimers. As a result, priming by
IFNa/b mediates enhanced IFNg/STAT1-dependent gene expres-
sion (Takaoka et al., 2000). A similar interaction has also been
observedforIFNARandIL-6/gp130signaling(Mitanietal.,2001).
ItwillbeinterestingtoinvestigatewhetherIFNARequallyinteracts
with IL-10 and IL-22 receptor complexes.
As already alluded to, upregulation of total STAT1 protein is
regardedafurthercrucialmechanismthatshouldlikewiseenhance
STAT1 signaling under the inﬂuence of type I IFN. Under those
conditions,augmentation of STAT1 function is already detectable
on the level of STAT1 phosphorylation (Sharif et al.,2004; Gough
etal.,2010;Bachmannetal.,2012).Infact,enhancedexpressionof
STAT1 is evident in monocytes of RA patients and translates into
increased IFNg sensitivity as detected by induction of classical
IFNg target genes (Karonitsch et al., 2012). Concomitant upreg-
ulation of IFNb at the inﬂamed synovium of RA patients (van
Holten et al., 2005) indicates clinical relevance of this regulatory
path. Interestingly, IFNb in the RA synovial compartment coin-
cides with increased levels of IL-10 (Cush et al., 1995) and IL-22
(Ikeuchi et al., 2005) at this location.
Finally, type I IFN apparently has the capability to upregu-
late IL-10R1 on human monocytes/macrophages and IL-22R1 on
human keratinocytes cultured in the context of living skin equiv-
alents (Liu et al., 2012; Tohyama et al., 2012). Those observations
suggest additional receptor-based mechanisms by which IFNa/b
may increase IL-10 and IL-22 biological activity.
CONCLUDING REMARKS
Type I IFN signiﬁcantly impacts on cytokine biology due to its
capacity to prime and thereby to quantitatively and qualitatively
modify cellular responses to cytokines. Accordingly, ﬁne-tuned
production of type I IFN is supposed to ensure appropriate tai-
loring of immunoactivation upon microbial/viral challenge. Its
inadequate production displayed either as decreased or increased
tissue IFN may either damp desired immunoactivation or, on the
other hand, predispose for overt inﬂammation, collateral tissue
damage, and autoimmunity (Gough et al., 2012). This hypothe-
sis article puts together and relates to a larger context the impact
of type I IFN on IL-10/IL-22 signaling. Present data suggest that
primingbytypeIIFNisabletotargetIL-10/IL-22cellularsignaling
towardSTAT1-drivenIFNg-likeactivation(seeFigure1).Current
knowledge on this potentially crucial IFNa/b-directed regulatory
path is primarily based on observations made on cultured cells,
among them primary macrophages and primary keratinocytes.
However, translated into the clinical setting one might specu-
late that in some patients such regulatory property of type I IFN
may profoundly affect outcome and side effects of immunomod-
ulatory therapy. Consequences of this hypothesis may apply to
current type I IFN treatment regimes but also to IL-10 or future
IL-22 clinical trials assessing their potential in anti-inﬂammatory
or tissue protective therapy. In this context it is noteworthy that
colitis-like symptoms are consistently detected in some patients
undergoing type I IFN therapy (Sprenger et al., 2005; Watanabe
et al., 2006; Schott et al., 2007). Looking at IL-22, it is tempt-
ing to relate those complications to constitutive IL-22 expression
by intestinal NK-like/innate lymphoid cell populations (Satoh-
Takayama et al., 2008; Sonnenberg et al., 2012) and pathogenic
properties of STAT1 in human colitis. In fact, intestinal STAT1
activation associates with severity of inﬂammatory symptoms in
ulcerative colitis and Crohn’s disease patients (Schreiber et al.,
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FIGURE 1 | Hypothesis: exploitation of IL-10 and IL-22 signaling by type I
IFN. Under “basal” conditions signal transduction of IL-10 (A) and IL-22 (B) is
dominated by activation of STAT3 in responsive cells types.Those are
primarily mononuclear phagocytes/DC or cells of epithelial origin for IL-10 or
IL-22, respectively. In this mode, IL-10 will lead to cellular deactivation
mediating a pronounced anti-inﬂammatory tissue response. Although
mechanistic details are still cloudy, temporally prolonged STAT3 activation is
pivotal for this regulatory path. Experimental data suggest direct or indirect
inhibition of NF-kB as one mode of STAT3 action which connects to
downregulation of key pro-inﬂammatory cytokines and effector molecules.
STAT3 activation by IL-22 facilitates proliferation and anti-apoptosis in epithelial
cells. Both of these processes would obviously favor tissue repair but likewise
tumor growth. Upon cellular priming by type I IFN, IL-10, and IL-22 signaling is
targeted toward surplus STAT1 activation (Sharif et al., 2004; Bachmann et al.,
2012) which, in contrast to STAT3, would supportTh1-like inﬂammation and
processes that favor apoptosis and control of tumor growth. Notably,
ampliﬁcation ofTh1-like inﬂammation may further enhance anti-bacterial
properties of IL-22 at host/environment interfaces.
2002). However, enforced IL-22-associated STAT1 activation may
not always be a disadvantage. Given the key anti-bacterial func-
tion of IL-22, supposed to be driven predominantly by STAT3,
acquisition of surplus IFNg-like biological activity might be an
advantage that further promotes efﬁcient host defense. Moreover,
increased STAT1 activation as a consequence of IL-22/type I IFN
interactions may counteract pro-tumorigenic STAT3 potentially
activatedbyexcessiveandprolongedexposuretoIL-22(Figure1).
Altogether, potential effects of IFN priming on IL-10/IL-22
signaling emphasized herein witness the complexity of cytokine
biology and may contribute to heterogeneous patient responses
recurrently observed in cytokine-based therapy.
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